Intravitreal tumor necrosis factor inhibitors in the treatment of refractory diabetic macular edema: A pilot study from the Pan-American collaborative retina study group

Retina

Volumn 31, Issue 2, 2011, Pages 298-303

  Wu, Lihteh ^a   Hernandez Bogantes, Erick ^a   Roca, José A ^b   Arevalo, J Fernando ^c   Barraza, Karen ^b   Lasave, Andres F ^c  

^a Instituto de Cirugia Ocular   (Costa Rica)

^b CLÍNICA RICARDO PALMA   (Peru)

^c Clinica Oftalmologica Centro Caracas   (Venezuela)

Author keywords

adalimumab; diabetic macular edema; Diabetic retinopathy; infliximab; intravitreal injection; tumor necrosis factor (TNF) ; uveitis

Indexed keywords

ADALIMUMAB; INFLIXIMAB; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DIABETIC MACULAR EDEMA; DISEASE EXACERBATION; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; HUMAN; INTERVENTION STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; OPTICAL RESOLUTION; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PILOT STUDY; REFRACTORY DIABETIC MACULAR EDEMA; RETINA FOVEA; RETROSPECTIVE STUDY; STEROID THERAPY; UVEITIS; VISUAL ACUITY; VITRECTOMY;

AGED; ANTI-INFLAMMATORY AGENTS; ANTIBODIES, MONOCLONAL; DIABETIC RETINOPATHY; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; HUMANS; INTRAVITREAL INJECTIONS; MACULA LUTEA; MACULAR EDEMA; MALE; MIDDLE AGED; PILOT PROJECTS; RETROSPECTIVE STUDIES; TOMOGRAPHY, OPTICAL COHERENCE; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA; VISUAL ACUITY;

EID: 79551528030     PISSN: 0275004X     EISSN: None     Source Type: Journal    
DOI: 10.1097/IAE.0b013e3181eac7a6     Document Type: Article

References (28)

1. Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XV. The long-term incidence of macular edema. Ophthalmology 1995;102:7-16.
2. Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1985;103:1796-1806.
3. Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009;127:245-251.
4. Singh A, Stewart JM. Pathophysiology of diabetic macular edema. Int Ophthalmol Clin 2009;49:1-11.
5. Grant MB, Afzal A, Spoerri P, Pan H, Shaw LC, Mames RN. The role of growth factors in the pathogenesis of diabetic retinopathy. Expert Opin Investig Drugs 2004;13:1275-1293.
6. Joussen AM, Doehmen S, Le ML, et al. TNF-alpha mediated apoptosis plays an important role in the development of early diabetic retinopathy and long-term histopathological alterations. Mol Vis 2009;15:1418-1428.
7. Joussen AM, Poulaki V, Mitsiades N, et al. Nonsteroidal antiinflammatory drugs prevent early diabetic retinopathy via TNF-alpha suppression. FASEB J 2002;16:438-440.
8. Sfikakis PP, Markomichelakis N, Theodossiadis GP, Grigoropoulos V, Katsilambros N, Theodossiadis PG. Regression of sight-threatening macular edema in type 2 diabetes following treatment with the anti-tumor necrosis factor monoclonal antibody infliximab. Diabetes Care 2005;28:445-447.
9. Khurana RN, Do DV, Nguyen QD. Anti-VEGF therapeutic approaches for diabetic macular edema. Int Ophthalmol Clin 2009;49:109-119.
10. Kuo CH, GilliesMC. Role of steroids in the treatment of diabetic macular edema. Int Ophthalmol Clin 2009;49:121-134.
11. Gillies MC, Simpson JM, Gaston C, et al. Five-year results of a randomized trial with open-label extension of triamcinolone acetonide for refractory diabetic macular edema. Ophthalmology 2009;116:2182-2187.
12. NguyenQD,ShahSM,Heier JS,etal.Primaryendpoint (sixmonths) results of the ranibizumab for edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009;116:2175-2181.e1.
13. Haritoglou C, Kook D, Neubauer A, et al. Intravitreal bevacizumab (Avastin) therapy for persistent diffuse diabetic macular edema. Retina 2006;26:999-1005.
14. Hawrami K, Hitman GA, Rema M, et al. An association in noninsulin- dependent diabetes mellitus subjects between susceptibility to retinopathy and tumor necrosis factor polymorphism. Hum Immunol 1996;46:49-54.
15. Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond) 2006;20:1366-1369.
16. Yuuki T, Kanda T, Kimura Y, et al. Inflammatory cytokines in vitreous fluid and serum of patients with diabetic vitreoretinopathy. J Diabetes Complications 2001;15:257-259.
17. Ben-Mahmud BM, Mann GE, Datti A, Orlacchio A, Kohner EM, Chibber R. Tumor necrosis factor-alpha in diabetic plasma increases the activity of core 2 GlcNAc-Tand adherence of human leukocytes to retinal endothelial cells: Significance of core 2 GlcNAc-T in diabetic retinopathy. Diabetes 2004;53:2968-2976.
18. Limb GA, Webster L, Soomro H, et al. Platelet expression of tumour necrosis factor-alpha (TNF-alpha), TNF receptors and intercellular adhesion molecule-1 (ICAM-1) in patients with proliferative diabetic retinopathy. Clin Exp Immunol 1999; 118:213-218.
19. Limb GA, Chignell AH, Green W, LeRoy F, Dumonde DC. Distribution of TNF alpha and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br J Ophthalmol 1996;80:168-173.
20. Suhler EB, Smith JR, Giles TR, et al. Infliximab therapy for refractory uveitis: 2-year results of a prospective trial. Arch Ophthalmol 2009;127:819-822.
21. Suhler EB, Smith JR, Wertheim MS, et al. A prospective trial of infliximab therapy for refractory uveitis: Preliminary safety and efficacy outcomes. Arch Ophthalmol 2005;123:903-912.
22. Giansanti F, Ramazzotti M, Vannozzi L, et al. A pilot study on ocular safety of intravitreal infliximab in a rabbit model. Invest Ophthalmol Vis Sci 2008;49:1151-1156.
23. Theodossiadis PG, Liarakos VS, Sfikakis PP, et al. Intravitreal administration of the anti-TNF monoclonal antibody infliximab in the rabbit. Graefes Arch Clin Exp Ophthalmol 2009; 247:273-281.
24. Theodossiadis PG, Liarakos VS, Sfikakis PP, Vergados IA, Theodossiadis GP. Intravitreal administration of the anti-tumor necrosis factor agent infliximab for neovascular age-relatedmacular degeneration. Am J Ophthalmol 2009;147:825-830, 830.e1.
25. Giganti M, Beer PM, Lemanski N, Hartman C, Schartman J, Falk N. Adverse events after intravitreal infliximab (Remicade). Retina 2010;30:71-80.
26. Tsilimbaris M, Diakonis VF, Naoumidi I, et al. Evaluation of potential retinal toxicity of adalimumab (Humira). Graefes Arch Clin Exp Ophthalmol 2009;247:1119-1125.
27. Manzano RP, Peyman GA, Carvounis PE, et al. Ocular toxicity of intravitreous adalimumab (Humira) in the rabbit. Graefes Arch Clin Exp Ophthalmol 2008;246:907-911.
28. Pulido JS, Pulido JE, Michet CJ, Vile RG. More questions than answers: A call for a moratorium on the use of intravitreal infliximab outside of a well-designed trial. Retina 2010;30:1-5.